Tumor Lysis Syndrome

Barbar, Tarek; Sathick, Insara Jaffer

doi:10.1053/j.ackd.2021.09.007

Cited by 34 publications

(22 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It predominantly occurs in the setting of hematological malignancies, particularly non‐Hodgkin’s lymphoma and acute leukemia 2 . It typically manifests with biochemical abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia 1,2 . Plasma cell leukemia (PCL) is an uncommon and aggressive variant of multiple myeloma with poor survival albeit with a clinically and genetically distinct profile 3,4 .…”

Section: Introductionmentioning

confidence: 99%

“…2 It typically manifests with biochemical abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. 1,2 Plasma cell leukemia (PCL) is an uncommon and aggressive variant of multiple myeloma with poor survival albeit with a clinically and genetically distinct profile. 3,4 In the following case report, we present a 62-year-old male patient with spontaneous TLS and hypercalcemia without a known malignancy, who is later discovered to have PCL.…”

Section: Introductionmentioning

confidence: 99%

“…Tumor lysis syndrome (TLS) is an oncologic emergency in which tumor cells undergo lysis either spontaneously or due to the initiation of cancer therapy. 1 It predominantly occurs in the setting of hematological malignancies, particularly non-Hodgkin's lymphoma and acute leukemia. 2 It typically manifests with biochemical abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia

Shafie

Issaiy

Barkhori

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia

Shafie

Issaiy

Barkhori

et al. 2022

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…However, in clinical trials, no incidence of TLS was observed in cancer patients treated with NIR-PIT 109 , 110 . Moreover, aggressive intravenous hydration and administration of hypouricemic agents significantly decrease the incidence of poor outcomes with TLS 111 . Nevertheless, a balance must be achieved between optimum antitumor effects and minimal toxicity to healthy tissues prior to clinical application.…”

Section: Potential Application Of Nir-pit For Cancer Treatmentmentioning

confidence: 99%

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Wei¹,

Qi²,

Hamblin³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment modality based on a target-specific photosensitizer conjugate (TSPC) composed of an NIR phthalocyanine photosensitizer and an antigen-specific recognition system. NIR-PIT has predominantly been used for targeted therapy of tumors via local irradiation with NIR light, following binding of TSPC to antigen-expressing cells. Physical stress-induced membrane damage is thought to be a major mechanism underlying NIR-PIT-triggered photokilling. Notably, NIR-PIT can rapidly induce immunogenic cell death and activate the adaptive immune response, thereby enabling its combination with immune checkpoint inhibitors. Furthermore, NIR-PIT-triggered “super-enhanced permeability and retention” effects can enhance drug delivery into tumors. Supported by its potential efficacy and safety, NIR-PIT is a rapidly developing therapeutic option for various cancers. Hence, this review seeks to provide an update on the (i) broad range of target molecules suitable for NIR-PIT, (ii) various types of receptor-selective ligands for designing the TSPC “magic bullet,” (iii) NIR light parameters, and (iv) strategies for enhancing the efficacy of NIR-PIT. Moreover, we review the potential application of NIR-PIT, including the specific design and efficacy in 19 different cancer types, and its clinical studies. Finally, we summarize possible NIR-PIT applications in noncancerous conditions, including infection, pain, itching, metabolic disease, autoimmune disease, and tissue engineering.

show abstract

“…Tumor lysis syndrome (TLS) represents a significant oncologic emergency often observed after treatment of hematologic malignancies by the release of intracellular contents into the blood 1 . Not surprisingly, when AKI develops in TLS patients, there is a significant increase risk of mortality 1 , 2 . Several excellent reviews have been written on the pathophysiology of the AKI in the setting of TLS, which largely highlight the hypothesis that AKI results from deposition of precipitated uric acid or calcium phosphate crystals in tubules 1 , 3 …”

mentioning

confidence: 99%

Crystals or His(stones): Rethinking AKI in Tumor Lysis Syndrome

Basile

2022

JASN

View full text Add to dashboard Cite

Tumor Lysis Syndrome

Cited by 34 publications

References 58 publications

Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia

Plasma cell leukemia presenting as spontaneous tumor lysis syndrome with hypercalcemia

Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond

Crystals or His(stones): Rethinking AKI in Tumor Lysis Syndrome

Contact Info

Product

Resources

About